- Research article
- Open Access
Long non‐coding RNA MALAT1 regulates cell proliferation and apoptosis via miR-135b-5p/GPNMB axis in Parkinson’s disease cell model
Biological Research volume 54, Article number: 10 (2021)
Parkinson’s disease (PD) is a common age-related neurodegenerative disorder worldwide. This research aimed to investigate the effects and mechanism underlying long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) in PD.
SK-N-SH and SK-N-BE cells were treated with MPP+ to establish the MPP+-stimulated cell model of PD, and MALAT1 expression was determined. Then, the effects of MALAT1 depletion on cell proliferation and apoptosis were determined in the MPP+-stimulated cell model of PD. Besides, the correlations between microRNA-135b-5p (miR-135b-5p) and MALAT1 or glycoprotein nonmetastatic melanoma protein B (GPNMB) in MPP+-stimulated cell model of PD were explored.
MALAT1 was increasingly expressed and downregulation of MALAT1 promoted cell proliferation while inhibited apoptosis in MPP+-stimulated cells. Besides, miR-135b-5p was a target of MALAT1 and directly targeted to GPNMB. Further investigation indicated that suppression of MALAT1 regulated cell proliferation and apoptosis by miR-135b-5p/GPNMB axis.
Our findings reveal that MALAT1/miR-135b-5p/GPNMB axis regulated cell proliferation and apoptosis in MPP+-stimulated cell model of PD, providing a potential biomarker and therapeutic target for PD.
MALAT1 was upregulated in MPP+-induced SK-N-SH and SK-N-BE cells.
MALAT1 depletion promoted cell proliferation and inhibited apoptosis in PD cell model.
MALAT1 upregulated GPNMN expression by sponging miR-135b-5p.
MALAT1 downregulation regulated MPP+-induced SK-N-SH and SK-N-BE cells proliferation and apoptosis by miR-135b-5p/GPNMB axis.
Parkinson’s disease (PD) is the second-most common neurodegenerative disease characterized by static tremors, bradykinesia, and cognitive dysfunction [1, 2]. According to epidemiological studies, approximately 1.7% of the Chinese population older than 65 years suffer from PD, which brings a heavy burden to patients’ families and society . Mounting evidence suggested that PD is associated with multiple factors, such as inflammatory response, oxidative stress, and cell apoptosis . There is numerous evidence suggesting that neuroinflammation is related to neurodegeneration in diverse neurological diseases . Despite several alternative therapies used in clinical medicine, effective treatment for PD is still limited . Thus, a better understanding of mechanism underlying PD and finding effective strategies for PD is urgently needed.
Long non-coding RNAs (lncRNAs), consist of more than 200 nucleotides, and have been reported to play essential roles in various human diseases [7,8,9]. A large mass of lncRNAs are found every year, and these lncRNAs are considered as “transcriptional noise” . However, recent studies have disclosed the functions of lncRNAs in human diseases, including PD. For example, nuclear paraspeckle assembly transcript 1 (NEAT1) was obviously increased in the brain region of Huntington’s disease patients . Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a well-known lncRNA, which has been proved to abnormal express in PD patients . Moreover, MALAT1 has also been revealed that was closely related to multiple diseases . Earlier studies have uncovered that MALAT1 regulated the development of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-stimulated PD cell model via modifying the expression of ɑ-synuclein . These results highlighted the decisive role of MALAT1 in PD. However, the biological role of MALAT1 in the pathogenesis of PD is not fully understood.
MiRNAs, a class of RNAs, are deemed to be promising biomarkers in clinical therapy of neurodegenerative diseases via addressing central nervous system homeostasis [15,16,17,18]. According to earlier works, miRNAs exert their functions through binding to 3’-untranslatedregion (3’-UTR) of targeted mRNAs to degrade mRNA or inhibit the following translation process, thereby inhibiting the expression of the target gene [19, 20]. MiR-135b-5p, one of the common members of miRNAs, has been explored to participate in the drug resistance in breast cancer . In addition, miR-135b-5p regulated cell metastasis and epithelial-mesenchymal transition (EMT) in gastric cancer by targeting CKLF-like MARVEL transmembrane domain containing 3 (CMTM3) . Interestingly, a recent study suggested that miR-135b exerted a protective role in PD through suppressing pyroptosis . Nevertheless, the role of miR-135b-5p in PD needs further investigation.
Glycoprotein non-metastatic melanoma protein B (GPNMB), a glycoprotein observed upon tissue damage and inflammation, the transcription of which is modulated by a microphthalmia-associated transcription factor (MITF) [24, 25]. Moreover, previous studies have shown that GPNMB level was selectively increased in PD patients [26, 27]. However, it is not unclear whether GPNMB was involved in MALAT1-mediated regulation in PD pathology.
As MPP+ could cause oxidative stress and mitochondrial dysfunction, thus injure dopaminergic neurons, leading to PD pathophysiology [28, 29], SK-N-SH and SK-N-BE cells were treated with MPP+ to establish the MPP+-stimulated cell model of PD, and we aimed to investigate the biological role and mechanism underlying MALAT1 in PD.
Materials and methods
Cell culture and treatment
Human neuroblastoma cells of SK-N-SH and SK-N-BE were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in Dulbecco’s modified Eagle medium (DMEM; Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco) and 1 × penicillin & streptomycin (Gibco, the final concentration of 100 U/mL penicillin and 100 µg/mL streptomycin). SK-N-SH or SK-N-BE cells re-suspended in complete medium were incubated under a humid atmosphere of 5% CO2 at 37 °C.
1-methyl-4-phenyl pyridinium (MPP+; Sigma-Aldrich, Louis, MO, USA) was used to establish PD cell model. To select the most appropriate concentration of MPP+, 0, 0.5, 1, 2, or 3 mM MPP+ were added into SK-N-SH and SK-N-BE cells, respectively. 2 mM was selected as the corresponding concentration for subsequent assays. Besides, SK-N-SH or SK-N-BE cells were pretreated with 100 µM MPP+ for 24 h to establish the in vitro cell model for PD.
Small interfering RNAs (siRNA) against MALT1 (si-MALAT1-1, si-MALAT1-2 or si-MALAT1-3) and its negative control (NC) were constructed. Overexpression vectors of MALAT1 (pcDNA3.0-MALAT1) and GPNMB (pcDNA3.0-GPNMB) were constructed by using pcDNA3.0, and pcDNA3.0 empty vector was used as negative control (pcDNA3.0-control). Besides, miR-135b-5p mimic (miR-135b-5p) and inhibitor (miR-135b-5p-inhibitor), as well as relative controls (miR-control as mimic control and miR-NC as inhibitor control) were constructed. These vectors or oligonucleotides were totally synthesized in KeyGEN Biotech. Cell transfection was conducted using lipofectamine 2000 (Invitrogen) in accordance with manufacturer’s instructions. In brief, 1 × 106 SK-N-SH and SK-N-BE cells were cultured on the 6-well plates and incubated to 70% confluence. Then the constructs were incubated with 10 µL lipofectamine 2000 reagent for 5 min at room temperature and incubated with cells for 24, 48 or 72 h, followed by treatment with 2 mM MPP+ for 24 h.
Cell viability detection
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide(MTT) assay was conducted to expose the capacity of cell proliferation. 1 × 104 SK-N-SH and SK-N-BE cells were seeded into a 96-well plate. After transfection for 0, 24, 48, or 72 h, respectively, 10 µl MTT solution (APExBIO Technology, Austin, TX, USA) was supplemented into each well, and then cells were cultured for another 4 h in the incubator at 37 °C. Then, dimethyl sulfoxide (DMSO; Absin Bioscience, Shanghai, China) was added to dissolve formazan. The absorbance value at 490 nm was detected using a microplate reader (Bio-Rad Laboratories, Philadelphia, PA, USA).
Quantitative real‐time polymerase chain reaction (qRT-PCR) assay
Total RNA was isolated and extracted from induced SK-N-SH and SK-N-BE cells by Trizol reagent (Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer’s instruction. First strand of complementary DNA (cDNA) was synthesized by utilizing Reverse Transcriptase M-MLV (Takara, Dalian, China). QRT-PCR was carried out to measure levels of MALAT1, miR-135b-5p and GPNMB via SYBR Green qPCR Master Mix (MedChemExpress, New Jersey, NJ, USA) reagent kit and ABI 7500 system (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s procedures. Relative levels of MALAT1, miR-135b-5p and GPNMB were calculated by 2−ΔΔCt method, glyceraldehyde-3-phosphate dehydrogenase (GAPDH for MALAT1 and GPNMB) or U6 (for miR-135b-5p) were used as the internal control. Primer sequences were listed: MALAT1 (forward: 5′-AAAGCAAGGTCTCCCCACAAG-3′; reverse: 5′-GGTCTGTGCTAGATCAAAAGGCA-3′); miR-135b-5p (forward: 5′-GGTATGGCTTTTCATTCCT-3′; reverse: 5′-CAGTGCGTGTCGTGGAGT-3′); GPNMB (forward: 5′-AAGTGAAAGATGTGTACGTGGTAACAG-3′; reverse: 5′-TCGGATGAATTTCGATCGTTCT-3′);GAPDH (forward: 5′-TGAACGGGAAGCTCACTGG-3′; reverse: 5′-TCCACCACCCTGTTGCTGTA-3′); U6 (forward: 5′-CTCGCTTCGGCAGCACA-3′; reverse: 5′-AACGCTTCACGAATTTGCGT-3′). The above sequences were synthesized in KeyGEN Biotech (Jiangsu, China).
Flow cytometry for cell apoptosis
Annexin V-FITC-fluorescein isothiocyanate/propidium iodide (Annexin V-FITC/PI) apoptosis detection kit (TransGen Biotech, Beijing, China) was employed to determine cell apoptosis in accordance with the manufacturer’s instruction. In brief, 1 × 106 SK-N-SH and SK-N-BE cells were collected and then resuspended with 1× binding buffer. Annexin V-FITC (5 µL) and PI (5 µL) were incubated with cell suspension for 15 min at room temperature in the dark. The apoptosis rate of SK-N-SH and SK-N-BE cells were assessed by a flow cytometry (FACS; BD Biosciences, San Jose, CA, USA) and analyzed with Flowjo software.
Total proteins were extracted from SK-N-SH and SK-N-BE cells using RIPA lysis buffer (Beyotime, Shanghai, China). Equal amount (20 µg) of total proteins were separated by gel electrophoresis with 12% SDS-polyacrylamide gel (SDS-PAGE), and then transfected onto the PVDF membranes (polyvinylidene fluoride; Millipore, Bedford, MA, USA). Subsequently, membranes were incubated with Tris-Buffered Saline Tween-20 (TBST; Solarbio, Beijing, China) supplemented with 5% bovine serum albumin for 1 h at room temperature. Then the membrane was cultivated overnight at 4 °C with primary antibodies purchased from Abcam (Abcam, Cambridge, MA, USA) which was diluted in TBST solution. The primary antibodies used in this research were shown as below: Cleaved-caspase 3 (Cleaved-casp-3; 1:500, ab13847), B-cell lymphoma-2 (Bcl-2; 1:1000, ab32124), Bcl-2-Associated X (Bax; 1:7000, ab32503), GPNMB (1:100, ab227695), PCNA (1: 1000, ab18197) and GAPDH (1:1000, ab8245). Subsequently, the membranes was washed with TBST for three times and then incubated with corresponding secondary antibody Goat Anti-Rabbit IgG H&L (1: 20,000, ab205718, Abcam) for 1 h at room temperature. Then the bands were visualized using High sensitivity ECL chemiluminescence detection kit (Vazyme, Nanjing, China) and quantified by Quantity One software version 4.6 (Bio-Rad Laboratories). GAPDH was used as the internal control.
Dual‐luciferase reporter assay
StarBaseV3.0 was employed to predict the potential targets of MALAT1 and miR-135b-5p. The sequences of MALAT1 or GPNMB 3’ non-translated regions (3’UTR) containing wild-type or mutant miR-135b-5p binding sites were amplified and then inserted into the pmirGLO (Promega, Madison, WI, USA) vectors to construct the recombinant luciferase reporter vectors, named as MALAT1-WT and MALAT1-MUT or GPNMB-WT and GPNMB-MUT, respectively. Then miR-135b-5p mimic or miR-control were co-transfected into SK-N-SH and SK-N-BE cells with the constructed luciferase reporter vectors. 48 h upon transfection, relative luciferase activities were identified using the dual-luciferase reporter assay kit (Promega). Each sample was performed thrice, and firefly luciferase activity was normalized to Renilla luciferase activity.
Statistical analysis was conducted by SPSS17.0. All data of three independent were presented as mean ± standard deviation (SD). The differences between the two groups were evaluated by Student’s t-test, and multiple statistical significance of the differences were analyzed by one-way ANOVA. P < 0.05 was considered as a significant difference.
MALAT1 was upregulated in MPP+-stimulated SK-N-SH and SK-N-BE cells
To investigate the expression of MALAT1 in PD, in vitro model of PD was established by MPP+-stimulated SK-N-SH and SK-N-BE cells. Firstly, SK-N-SH and SK-N-BE cells were cultured with different concentrations of MPP+ (0 mM, 0.5 mM, 1 mM, 2 mM, or 3 mM), cells with neuron-like morphology express synapse-specific proteins and display synaptic structures were chosen for further research (Additional file 1: Figure S1). MTT assay indicated that cell viability was significantly decreased in high concentration of MPP+-treated (2, and 3 mM) SK-N-SH and SK-N-BE cells (Fig. 1a and b), compared to untreated group. Besides, the level of MALAT1 was markedly increased in a concentration-dependent manner in SK-N-SH and SK-N-BE cells, especially in high levels of MPP+ treatment group (2, and 3 mM) (Fig. 1c and d). Therefore, 2 mM MPP+ was selected as the treatment conditions for subsequent experiments.
MALAT1 knockdown contributed to cell proliferation, curbed apoptosis in MPP+-stimulated SK-N-SH and SK-N-BE cells
To determine the role of MALAT1 in PD, loss-of-function experiments were performed by transfecting si-NC or si-MALAT1 in MPP+-stimulated SK-N-SH and SK-N-BE cells. As shown in Fig. 2a and b, MALAT1 expression was reduced by half in cells with si-MALAT1-1, si-MALAT1-2, or si-MALAT1-3 transfection compared to si-NC group. The knockdown efficiency of si-MALAT1-1 was more distinctly than the others, hence, si-MALAT1-1 was chosen for further study. MTT assay indicated that downregulation of MALAT1 increased cell viability in contrast with the cells with si-NC transfected group in MPP+-stimulated SK-N-SH and SK-N-BE cells (Fig. 2c and d). Besides, flow cytometry assay was used to determine cell apoptosis rate, and the results indicated that cell apoptosis was remarkably curbed by MALAT1 depletion (Fig. 2e). And it was further confirmed by the decreased protein levels of Bax (pro-apoptotic protein) and Cleaved-casp-3 (marker for apoptosis) and the elevated level of Bcl-2 (anti-apoptotic protein) protein in cells with MALAT1 downregulation (Fig. 2f and g). Besides, we also evaluated the protein level of PCNA (cell division marker) in transfected cells. As shown in Fig. 2h, the protein level of PCNA was doubled in cells with MALAT1 knockdown, explaining the increased cell viability in cells with si-MALAT1 transfection. Thus, downregulation of MALAT1 promoted cell proliferation but inhibited cell apoptosis in MPP+-stimulated SK-N-SH and SK-N-BE cells.
MALAT1 acted as a miRNA sponge for miR-135b-5p
To investigate the mechanism underlying MALAT1 in PD, the bioinformatics tool StarbaseV3.0 was used to predict the target miRNAs of MALAT1. As shown in Fig. 3a, MALAT1 harbored complementary binding sites of miR-135b-5p. To verify whether MALAT1 was interacted with miR-135b-5p, dual-luciferase reporter assay was employed. Compared with the miR-control transfected group, transfection of miR-135b-5p obviously inhibited the luciferase activity of MALAT1-WT group, while it had little effect on the luciferase activity of MALAT1-MUT group (Fig. 3b, c), demonstrating their potential endogenous interaction in SK-N-SH and SK-N-BE cells. In addition, miR-135b-5p expression was remarkably increased by MALAT1 knockdown (Fig. 3d), and was markedly decreased by the miR-135b-5p inhibitor (Fig. 3e). Next, to investigate whether MALAT1 regulated cell behaviors by miR-135b-5p, SK-N-SH and SK-N-BE cells were transfected with si-NC, si-MALAT1, si-MALAT1 + miR-NC or si-MALAT1 + miR-135b-5p-inhibitor, respectively. We found that miR-135b-5p inhibitor reversed the promotion effect of si-MALAT1 on cell viability (Fig. 3f and g). And miR-135b-5p inhibitor rescued cell apoptosis that was repressed by MALAT1 knockdown, as the apoptosis rate was decreased by si-MALAT1, but was increased by co-transfection of miR-135b-5p inhibitor (Fig. 3h). And si-MALT1-mediated the suppression on the protein levels of Bax and Cleaved-casp-3, and the promotion on Bcl-2 protein, were reversed by miR-135b-5p inhibitor (Fig. 3i, j). Besides, the elevated protein level of PCNA that induced by si-MALAT1 was reversed by miR-135b-5p inhibitor (Fig. 3k). These results indicated that MALAT1 knockdown regulated proliferation and apoptosis of MPP+-stimulated SK-N-SH and SK-N-BE cells via regulating miR-135b-5p.
MiR-135b-5p directly targeted GPNMB
To further explore the underlying mechanism of miR-135b-5p in PD, StarBase3.0 software was applied to predict the potential target of miR-135b-5p, and the results revealed that GPNMB might be target by miR-135b-5p (Fig. 4a). Subsequently, dual-luciferase reporter assay displayed that miR-135b-5p could significantly lower the luciferase activity of GPNMB-WT group without significant influence on the luciferase activity of GPNMB-MUT. However, this inhibitory effect of GPNMB-WT and miR-135b-5p mimic on luciferase activity was rescued by co-transfection of pcDNA-MALAT1 (Fig. 4b, c), indicating the potential endogenous interaction in SK-N-SH and SK-N-BE cells. To investigate whether GPNMB was regulated by miR-135b-5p and MALAT1, miR-control, miR-135b-5p, miR-135b-5p + pcDNA-control, or miR-135b-5p + pcDNA-MALAT1 was transfected into MPP+-induced SK-N-SH and SK-N-BE cells, qRT-PCR assay implied that miR-135b-5p mimic obviously inhibited mRNA and protein levels of GPNMB, while these inhibiting effects were reversed by transfection of pcDNA-MALAT1 (Fig. 4d and g). The results implicated that MALAT1 regulated GPNMB expression by sponging miR-135b-5p.
Upregulation of GPNMB abolished the effect of MALAT1 knockdown on cell proliferation and apoptosis in MPP+-stimulated SK-N-SH and SK-N-BE cells
Then, the regulatory mechanism of GPNMB in PD was further confirmed. Firstly, the over-expressed efficiency of pcDNA3.0-GPNMB was confirmed by qRT-PCR and western blot assay (Fig. 5a and b). And MTT assay revealed that upregulation of GPNMB reversed the promotion effect of MALAT1 knockdown on cell viability (Fig. 5c and d). Besides, the effect of MALAT1 knockdown on cell apoptosis was also reversed by GPNMB upregulation (Fig. 5e–g). Furthermore, overexpression of GPNMB also reversed the elevated protein level of PCNA that mediated by si-MALAT1, indicating that upregulation of GPNMB promoted cell proliferation of MPP+-stimulated SK-N-SH and SK-N-BE cells (Fig. 5h). Thus, MALAT1 could regulate cell proliferation and apoptosis by miR-135b-5p/GPNMB aixs in MPP+-stimulated SK-N-SH and SK-N-BE cells.
PD is a neurological disorder that affects the movement abilities of adults [1, 2], which remains lack of effective therapeutic measures due to the limited understanding of the dysfunction of molecular events and signaling pathways underlying neurodegeneration . In the present research, MPP+, the active metabolite of MPTP, was used to stimulate SK-N-BE and SK-N-BE cells, thereby established PD cell model according to previous descriptions [30, 31]. We found that MALAT1 was highly expressed in MPP+-induced SK-N-BE and SK-N-BE cells. Meanwhile, cell viability was notably decreased in SK-N-BE and SK-N-BE cells with the increasing concentration of MPP+.
It has been reported that MALAT1 was highly expressed in neurons, and the aberrant expression of MALAT1 could regulate target gene expression associated with synapse formation . Besides, Liu et al. indicated that MALAT1 promoted the apoptosis by sponging miR-124 in mouse models of PD and in vitro model of PD . Cai et al. showed that MALAT1 could induce inflammasome activation and reactive oxygen species (ROS) production in PD mouse and microglial cell models by epigenetically inhibiting NRF2 . Consistent with previous research, in our study, MALAT1 depletion rescued the decreased cell proliferation and increased apoptosis in MPP+-treated SK-N-BE and SK-N-BE cells, indicating the pivotal role of MALAT1 in the apoptosis of neurons in PD.
Extensive research suggested that lncRNAs could act as the molecular sponge of miRNAs to negatively regulate its expression and thus regulating biological functions . In this study, we firstly found that miR-135b-5p was a target miRNA of MALAT1. Sufficient evidence suggested that miR-135b-5p exhibited multiple biological functions in human disease [36,37,38]. Ren et al. indicated that miR-135b-5p regulated the proliferation and apoptosis of ovarian cancer . Zhang et al. suggested that miR-135b-5p promoted cells migration, invasion and EMT in pancreatic cancer cells . Besides, Huang et al. indicated that miR-135b-5p could reduce neuronal injury and inflammatory response in post-stroke cognitive impairment . A recent research also showed that miR-135b-5p was aberrantly expressed in dopaminergic neurons of PD patients, whereas the research of miR-135b-5p functional effect in PD was limited . In our research, downregulation of miR-135b-5p partly reversed the elevated cell proliferation and decreasing cell apoptosis which was mediated by MALAT1 knockdown, indicating the protect role of miR-135b-5p in MPP+-stimulated SK-N-SH and SK-N-BE cells.
MiRNAs could regulate expression of genes at post-transcriptional level by binding 3’UTR of mRNA. Tumor suppressor gene adenomatous polyposis coli (APC) , oncogene forkhead box O1 (FOXO1) , Anterior Gradient 2 (AGR2)  and cyclin-associated protein cyclin D2  were reported as the target genes of miR-135b-5p. In our research, we found that miR-135b-5p was interacted with GPNMB, and the interaction between miR-135b-5p and GPNMB was further confirmed by subsequent dual-luciferase reporter assay. It was reported that GPNMB was abnormal expressed in various cells [24, 44]. Besides, genome-wide association studies demonstrated that GPNMB should be considered as possible Parkinson’s disease-related genes for future studies . Thus, we further investigate the effect of GPNMB in MALAT1/miR-135b-5p regulated the proliferation and apoptosis of neurons in PD. In the present study, we revealed that MALAT1 upregulated GPNMB protein level by inhibiting miR-135b-5p, thereby regulating cell proliferation and apoptosis in MPP+-stimulated SK-N-SH and SK-N-BE cells.
Taken together, MALAT1 expression was increased in MPP+-induced SK-N-BE and SK-N-BE cells. Knockdown of MALAT1 promoted cell proliferation, and hamper apoptosis in MPP+-induced SK-N-SH and SK-N-BE cells. MALAT1 interacted with miR-135b-5p to regulate GPNMB expression (Fig. 6). Our results highlight the potential of MALAT1/miR-135b-5p/GPNMB network in PD cell model, and provide a potential therapeutic target for PD. However, more efforts should be given to elaborate the regulatory network of lncRNA/miRNA/mRNA as central player in PD.
Availability of data and materials
All data generated and analysed during this study are included in this published article are available on request.
Kalia LV, Lang AE. Parkinson disease in 2015: evolving basic, pathologicaland clinical concepts in PD. Nat Rev Neurol. 2016;12:65.
Sveinbjornsdottir S. The clinical symptoms of Parkinson’s disease. J Neurochem. 2016;139:318–24.
Ma CL, Su L, Xie JJ, Long JX, Wu P, Gu L. The prevalence and incidence of Parkinson’sdisease in China: a systematic review and meta-analysis. J Neural Transm (Vienna). 2014;121:123–34.
Andican G, Konukoglu D, Bozluolcay M, Bayülkem K, Firtiına S, Burcak G. Plasma oxidative and inflammatory markers in patients with idiopathic Parkinson’s disease. Acta Neurol Belg. 2012;112:155–9.
Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science. 2016;353:777–83.
Kabra A, Rohit S, Ruchika K, Baghel US. Emerging and alternative therapies for Parkinson disease: an updated review. Curr Pharm Des. 2018;24:2573–82.
Paola R, Antonia R, Marco V. The long non-coding RNAs in neurodegenerative diseases: novel mechanisms of pathogenesis. Curr Alzheimer Res. 2016;13:1219–31.
Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29:452–63.
Ping WZ, Xialin D, Houliang L, Xiaoxia L, Li JA. Roles of long noncoding RNAs in brain development, functional diversification and neurodegenerative diseases. Brain Res Bull. 2013;97:69–80.
Chris P, Ponting O, Peter L, Wolf R. Evolution and functions of long noncoding RNAs. Cell. 2009;136:629–41.
Johnson R. Long non-coding RNAs in Huntington’s disease neurodegeneration. Neurobiol Dis. 2012;46:245–54.
Theo FJ, Kraus H, Melanie S, Judith S, Martina D, Vanessa MD. Altered long noncoding RNA expression precedes the course of Parkinson’s disease—a preliminary report. Mol Neurobiol. 2017;54:2869–77.
Zhao M, Songpo W, Qi L, Qing J, Piaoting G, Liu X. MALAT1: a long non–coding RNA highly associated with human cancers. Oncol Lett. 2018;16:19–26.
Zhang Q-S, Wang Z-H, Zhang J-L, Duan Y-L, Li G-F, Zheng D-L. Beta-asarone protects against MPTP-induced Parkinson’s disease via regulating long non-coding RNA MALAT1 and inhibiting α-synuclein protein expression. Biomed Pharmacother. 2016;83:153–9.
Nelson PT, Wang W-X, Rajeev BW. MicroRNAs (miRNAs) in neurodegenerative diseases. Brain Pathol. 2008;18:130–8.
Mika Shioya O, Shinya T, Hiroko A, Kunimasa S, Saito Y, Ishida T, Satoh J. Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3. Neuropathol Appl Neurobiol. 2010;36:320–30.
Hébert SS, De Strooper B. Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci. 2009;32:199–206.
Hébert SS, De Strooper B. miRNAs in neurodegeneration. Science. 2007;317:1179–80.
Gandellini P, Valentina D, Zaffaroni N, editors. microRNAs as players and signals in the metastatic cascade: Implications for the development of novel anti-metastatic therapies. Amsterdam: Elsevier. 2017.
Lu J, Licheng T, Xu Y, Kuikui G, Jinjiang H, Gu M, Jiang Z, Huang Q. Mir-1287 suppresses the proliferation, invasion, and migration in hepatocellular carcinoma by targeting PIK3R3. J Cell Biochem. 2018;119:9229–38.
Zhang Y, Zhang XF, Yingying FC, Qingling W, Hui L, Wu Y. miR-135b-5p enhances doxorubicin-sensitivity of breast cancer cells through targeting anterior gradient 2. J Exp Clin Cancer Res. 2019;38:26.
Lu M, Huang Y, Sun W, Li P, Li L, Li L. miR-135b-5p promotes gastric cancer progression by targeting CMTM3. Int J Oncol. 2018;52:589–98.
Zeng R, Luo D, Li H, Zhang Q, Lei S, Chen J. MicroRNA-135b alleviates MPP-mediated Parkinson’s disease in in vitro model through suppressing FoxO1-induced NLRP3 inflammasome and pyroptosis. J Clin Neurosci. 2019;65:125–33.
Vera M, Ripoll M, Nicholas A, Raggatt LJ, Ming K, Pettit Allison R, Cassady Alan I, Hume David A. Microphthalmia transcription factor regulates the expression of the novel osteoclast factor GPNMB. Gene. 2008;413:32–41.
Loftus SK, Anthony A, Ivana M, Gabriel R, Baxter LL, Reid D, Wolfsberg TG, Chen Y, Wang CW, Program NISC Comparative Sequencing. Gpnmb is a melanoblast-expressed, MITF-dependent gene. Pigment cell & melanoma research. 2009;22:99–110.
Elizabeth B, Moloney A, Moskites, Eliza J, Ferrari O, Isacson, Penelope J, Hallett. The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson’s disease patients and increases after lysosomal stress. Neurobiol Dis. 2018;120:1–11.
Megha N, Murthy C, Blauwendraat UKBEC, Sebastian Guelfi IPDGC, JohnHardy PA, Lewis, Daniah Trabzuni. Increased brain expression of GPNMB is associated with genome wide significant risk for Parkinson’s disease on chromosome 7p15.3. Neurogenetics. 2017;18:121–33.
Fornai F, Schlüter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, Lazzeri G, Busceti CL, Pontarelli F, Battaglia G, Pellegrini A, Nicoletti F, Ruggieri S, Paparelli A, Südhof TC. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci U S A. 2005;102:3413–8.
Chun HS, Gibson GE, DeGiorgio LA, Zhang H, Kidd VJ, Son JH. Dopaminergic cell death induced by MPP(+), oxidant and specific neurotoxicants shares the common molecular mechanism. J Neurochem. 2001;76:1010–21.
Lan Y-L, Zhou J-J, Liu J, Huo X-K, Wang Y-L, Liang J-H, Zhao J-C, Sun C-P, Yu Z-L, Fang L-L. Uncaria rhynchophylla Ameliorates Parkinson’s Disease by Inhibiting HSP90 Expression: Insights from Quantitative Proteomics. Cell Physiol Biochem. 2018;47:1453–64.
Hare DJ, Adlard PA, Doble PA, Finkelstein DI. Metallobiology of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine neurotoxicity. Metallomics. 2013;5:91–109.
Bernard D, Prasanth KV, Tripathi V, Colasse S, Nakamura T, Xuan Z, Zhang MQ, Sedel F, Jourdren L, Coulpier F. A long nuclear-retained non-coding RNA regulates synaptogenesis by modulating gene expression. EMBO J. 2010;29:3082–93.
Liu W, Zhang Q, Zhang J, Pan W, Zhao J, Xu Y. Long non-coding RNA MALAT1 contributes to cell apoptosis by sponging miR-124 in Parkinson disease. Cell Biosci. 2017;7:19.
Cai LJ, Tu L, Huang XM, Huang J, Qiu N, Xie GH, Liao JX, Du W, Zhang YY, Tian JY. LncRNA MALAT1 facilitates inflammasome activation via epigenetic suppression of Nrf2 in Parkinson’s disease. Mol Brain. 2020;13:130.
Lucas T, Bonauer A, Dimmeler S. RNA Therapeutics in Cardiovascular Disease. Circ Res. 2018;123:205–20.
Ren R, Wu J, Zhou MY. MiR-135b-5p affected malignant behaviors of ovarian cancer cells by targeting KDM5B. Eur Rev Med Pharmacol Sci. 2020;24:3548–54.
Zhang Z, Che X, Yang N, Bai Z, Wu Y, Zhao L, Pei H. miR-135b-5p Promotes migration, invasion and EMT of pancreatic cancer cells by targeting NR3C2. Biomed Pharmacother. 2017;96:1341–8.
Huang Y, Wang Y, Ouyang Y. Elevated microRNA-135b-5p relieves neuronal injury and inflammation in post-stroke cognitive impairment by targeting NR3C2. Int J Neurosci. 2020. https://doi.org/10.1080/00207454.2020.1802265.
Tolosa E, Botta-Orfila T, Morató X, Calatayud C, Ferrer-Lorente R, Martí MJ, Fernández M, Gaig C, Raya Á, Consiglio A, Ezquerra M, Fernández-Santiago R. MicroRNA alterations in iPSC-derived dopaminergic neurons from Parkinson disease patients. Neurobiol Aging. 2018;69:283–91.
Zhao CC, Jiao Y, Zhang YY, Ning J, Zhang YR, Xu J, Wei W, Kang-Sheng G. Lnc SMAD5-AS1 as ceRNA inhibit proliferation of diffuse large B cell lymphoma via Wnt/β-catenin pathway by sponging miR-135b-5p to elevate expression of APC. Cell Death Dis. 2019;10:252.
Ding B, Yao M, Fan W, Lou W. Whole-transcriptome analysis reveals a potential hsa_circ_0001955/hsa_circ_0000977-mediated miRNA-mRNA regulatory sub-network in colorectal cancer. Aging. 2020;12:5259–79.
Zhang Y, Xia F, Zhang F, Cui Y, Wang Q, Liu H, Wu Y. miR-135b-5p enhances doxorubicin-sensitivity of breast cancer cells through targeting anterior gradient 2. J Exp Clin Cancer Res. 2019;38:26.
Li Z, Qin Y, Chen P, Luo Q, Shi H, Jiang X. miR–135b–5p enhances the sensitivity of HER–2 positive breast cancer to trastuzumab via binding to cyclin D2. Int J Mol Med. 2020;46:1514–24.
Szulzewsky F, Pelz A, Feng X, Synowitz M, Markovic D, Langmann T, Holtman IR, Wang X, Eggen BJL, Boddeke HWGM. Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1. PLoS One. 2015;10:e0116644.
Rudakou U, Yu E, Krohn L, Ruskey JA, Asayesh F, Dauvilliers Y, Spiegelman D, Greenbaum L, Fahn S, Waters CH, Dupré N, Rouleau GA, Hassin-Baer S, Fon EA, Alcalay RN, Gan-Or Z. Targeted sequencing of Parkinson’s disease loci genes highlights SYT11, FGF20 and other associations. Brain. 2020. https://doi.org/10.1093/brain/awaa401.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The levels of TUJ1 and VMAT2 during the cells with MPP+ treatment. Cells were treated with 2mM MPP+ for 6 days, and the expression of TUJ1 and VMAT2 were detected by qRT-PCR.
About this article
Cite this article
Lv, K., Liu, Y., Zheng, Y. et al. Long non‐coding RNA MALAT1 regulates cell proliferation and apoptosis via miR-135b-5p/GPNMB axis in Parkinson’s disease cell model. Biol Res 54, 10 (2021). https://doi.org/10.1186/s40659-021-00332-8
- Parkinson’s disease
- Cell proliferation